The wrong prescription for drug affordability
The Medication Affordability and Patent Integrity Act would create new regulatory burdens on biotech companies, making it harder and taking longer to develop new treatments, while doing nothing to lower prescription drug prices.
The Medication Affordability and Patent Integrity Act would create new regulatory burdens on biotech companies, making it harder and taking longer to develop new treatments, while doing nothing to lower prescription drug prices.
Summary aggregated from The Hill's public RSS feed. The full reporting belongs to The Hill — please read it on their site.